EU health chief to probe effects of Trump’s drug pricing push

EU health officials are looking into how President Trump's push for lower drug prices in the U.S. might affect Europe's healthcare system. The European Health Commissioner will evaluate the potential impact of the "most-favored-nation" policy, which aims to keep U.S. drug prices low compared to other countries. This investigation is significant because it could reveal broader implications for international drug pricing strategies and healthcare costs in the EU, potentially reshaping how medications are priced and accessed globally.